Ratings Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Market Closed - Nasdaq Other stock markets 21:00:00 06/09/2024 BST			5-day change	1st Jan Change
22.22 ^USD	-4.43%		-6.76%	-27.39%

09-03	Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday	MT
09-03	Transcript : Arrowhead Pharmaceuticals, Inc. - Shareholder/Analyst Call

Summary: Arrowhead Pharmaceuticals, Inc.

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
According to Refinitiv, the company's ESG score for its industry is poor.

Highlights: Arrowhead Pharmaceuticals, Inc.

Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses: Arrowhead Pharmaceuticals, Inc.

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings Chart: Arrowhead Pharmaceuticals, Inc.

Source: Surperformance

ESG chart: Arrowhead Pharmaceuticals, Inc.

Source: Refinitiv

Sector Comparison:

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	Capi. ($)
ARROWHEAD PHARMACEUTICALS, INC.	-	2.76B
REGENERON PHARMACEUTICALS, INC.		122B
VERTEX PHARMACEUTICALS INCORPORATED		121B
ARGENX SE	-	32.37B
BIONTECH SE	-	21.38B
BEIGENE, LTD.	-	20.33B
GENMAB A/S		17.58B
WUXI APPTEC CO., LTD.		15.54B
SAREPTA THERAPEUTICS, INC.		12.29B
Average		40.58B
Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

C-

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes